clinical trial · NCT02260557
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Raynaud's Phenomenon Secondary to Systemic SclerosisSelexipagPlacebo
brief summary
The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).
started
Oct 31, 2014
primary completion
Apr 30, 2015
completion
Jun 30, 2015
last updated
Jun 3, 2026
official title
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol